Categories

  • Upcoming Events
  • News
  • YAFO Global Life Science Weekly

Follow us on Wechat

YAFO Acts as Financial Advisor for SIFI S.p.A. in Establishing Joint Venture with AffaMed Therapeutics

March 31, 2021

The Joint Venture obtains the right to develop, manufacture and commercialize premium innovative intraocular lenses ("IOLs") in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong.

YAFO Acts as Exclusive Financial Advisor for ImmuneOncia Therapeutics in its Licensing-out Transaction with 3D Medicines

March 31, 2021

ImmuneOncia Therapeutics, Inc. signs exclusive license agreement with 3D Medicines, Inc. for the development, manufacture, and commercialization of IMC-002. The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China.

ACCESS CHINA Spring Forum 2021 | China Out-Licensing Event

March 18th-19th, 2021

Hundreds of biopharma executives congregated for ACCESS CHINA to meet with the potential partners for development, licensing or commercial collaborations. The two-day conference agenda included company presentations and panel discussion.

YAFO CAPITAL Announces the Establishment of China Division and the Promotion

March 16, 2020

YAFO CAPITAL Announces the Establishment of China Division,Victor Ye as the Managing partner to Lead YAFO’s China Division,Gian Andrea Dell Antonio Promoted to Vice President – Europe Region

YAFO Acts as Financial Advisor for Starton Therapeutics in its Licensing-out Transaction with Haisco Pharma

March 1st, 2021

Starton Therapeutics entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ in Mainland China with Haisco Pharmaceuticals co,. LTD.

YAFO Acts as Exclusive Financial Advisor for AUM Biosciences in its collaboration & Licensing-out Transaction with Newsoara Biopharma

Nov 18th 2020

November 18, 2020, Singapore – AUM Biosciences (AUM), a global, clinical stage healthcare company focused on discovering, acquiring and developing novel oncology therapeutics and Newsoara Biopharma announced today that the companies have entered into a 5-year strategic partnership to co-develop up to 6 oncology drugs in AUM’s pipeline.

YAFO Acts as Exclusive Financial Advisor for Rhizen Pharmaceuticals in its Licensing-out Transaction with Curon Biopharma

Oct 12th 2020

Rhizen Pharmaceuticals (Rhizen Pharmaceuticals, S.A.) signs exclusive license agreement with Curon Biopharma (Curon Biopharmaceutical Limited) for the development and commercialization of Tenalisib in Greater China

YAFO Capital (Shanghai) Announces Expansion in Europe and Joint Venture with FCF Fox Corporate Finance

June 18th 2020

Shanghai/Munich, June 18, 2020 – The Life Sciences team at YAFO Capital is expanding its European network with a new joint venture. Germany advisory firm FCF Fox Corporate Finance is the most recent addition to the roster of renowned international partners working with the Shanghai-based life science specialist. “We look forward to expanding our partnership with FCF and providing the best landing platform for European biopharma and medtech companies to access China, as well as helping YAFO’s Chinese biopharma clients to access Europe.” says Sean Jiang, CEO & Founder of YAFO Capital. “Over the last seven years, YAFO has built a solid institutional investor base and broad coverage of over 500 pharma, biotech, and medtech companies in Asia. We hope our investor base and expertise can benefit European companies when penetrating the Asian market.“ comments Fan Zheng, Managing Director of YAFO Life Science.

YAFO Acts as Exclusive Financial Advisor for Flexion Therapeutics in its Licensing-out Transaction with Tainuo

April 1st 2020

Flexion signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (Jiangsu Tainuo) for the development and commercialization of ZILRETTA® in Greater China

YAFO CAPITAL Grows Life Science Team and Launches China Out-Licensing Division

April 1st 2020

YAFO Capital, a Shanghai-based boutique investment & advisory firm focused on helping leading U.S. and European biopharma and MedTech companies successfully enter the Asian market, is pleased to announce the recent expansion of its life science team and the launching of China out-licensing division. 

MEDICAL MASKS FOR FREE – UNITED TO FIGHT AGAIST COVID-19 TOGETHER

March 27th 2020

As part of our collective effort to fight against the Coronavirus, we would be happy to ship to our partners some medical masks for free. Shipping to certain countries is already restricted but some are still possible. Please let us know if you or your family members may need. Contact: wxiang@yafocapital.com

UNITED TO FIGHT AGAIST COVID-19 TOGETHER!

March 20th 2020

Partnering with YAFO’s broad medical clients, we are happy to help bridge global demands for Chinese medical suppliers:

YAFO Acts as Exclusive Financial Advisor for Tarveda Therapeutics in its Licensing-out Transaction with SciClone

March 16th 2020

Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, and SciClone Pharmaceuticals International Ltd., (“SciClone”) today announced that they have entered into a licensing agreement for PEN-866, the initial clinical program from Tarveda’s HSP90 binding miniature drug conjugate platform, which is designed to bind to the activated form of Heat Shock Protein 90 (HSP90) to accumulate and release its potent topoisomerase 1 inhibitor (SN-38) payload in solid tumors.

"East Meets West" JPM Mixing Dinner Was Successfully Held in San Francisco

January 15, 2020

Our "East Meets West" JPM Mixing Dinner reception held successfully welcomed a good mix of 185 executives from pharmaceutical, biotech, life science investors, and financial institutions, including about half from China and Japan and half from U.S., EU and ROW.

雅法中日美企业交流晚宴在旧金山成功举办

January 15, 2020

由雅法资本和Renexes共同主办,CHBD、美安医药、东玉咨询赞助的JPM中美日交流晚宴(East Meets West JPM Mixing Dinner)于2020年1月15日在美国旧金山圆满落幕!报名参会人数185人,均为来自中国(50家药企)、日本(20家药企)、美国欧洲及海外其他国家的生物技术公司(80家)、医药上市公司、基金等机构的管理层。

Yafo CEO Speaks at 19th Annual Biotech in Europe Forum

Sept 25, 2019

Sean Jiang, the CEO of Yafo Capital, participated 19th Annual Biotech in Europe Forum from 25th - 26th September 2019 at the Congress Center Basel, Switzerland. The forum provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. Over 700 delegates and over 100 presenting companies, and 30+ pitches by seed companies have been involved.

YAFO Received “2019 Best Pharma BD Innovation Award”

September 11, 2019

Yafo capital received the “2019 Best Pharma BD Innovation Award” at the 14th China Pharmaceutical and Medtech Business Development Forum, hosted by Luye Pharmaceutical and Weijian Pharmaceutical. The Forum is organized by China Healthcare Business Development (CHBD) and Yafo Capital acts as the Forum’s designated transaction partner. Yafo Capital presented 4 overseas pharma transaction opportunities at the conference.

YAFO Host the 4th China Pharma BD Salon with Ferring

August 30, 2019

YAFO Capital office welcomed more than 20 pharmaceutical leaders to join the salon, including executives and BD Directors from Ferring Pharmaceuticals, Sinopharma, Tasly Group, CR Pharmaceutical, Wuxi Apptec, Tenry Pharmaceutical, etc.

BIOMERICA SIGNS EXCLUSIVE COMMERCIAL AGREEMENT WITH MAXHEALTH IN CHINA,YAFO CAPITAL ACTED AS THE EXCLUSIVE FINANCIAL ADVISOR ON THIS TRANSACTION

June 05, 2019

IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect product in China. The agreement requires MaxHealth to meet annual minimum purchase requirements, which in aggregate, equal $17 million. As previously announced, the CFDA has already cleared Biomerica’s EZ Detect™ colorectal screening test for distribution in China.

Yangtze River Pharmaceutical Group (YRPG) Visits YAFO Office to Discuss Cross-boarder Opportunities

June 3rd, 2019

On June 3rd, 2019, Mr. Cai Wei, the head of R&D Center of Yangtze River Pharmaceutical Group(YRPG), visited YAFO Capital Shanghai office with its team. YRPG has ranked No. 1 for many years among all Chinese pharmaceutical companies (Data reported by China Ministry of Industry and Information Technology).

Sean Jiang speaks at Meet Up Session at JHVS on October 12th, 2018 in Yokohama

October 12th, 2018

Comparing to the US and China, number of successful start-ups and bioventures in the healthcare sector are fewer in Japan nevertheless there are many cutting edge disruptive science from Japanese academia. What are the reasons behind?

Yafo Capital Acts as Exclusive Advisor for Synergy Pharma (SGYP) in its $68 Million Licensing Transaction

August 7, 2018

August 8, 2018 - Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced yesterday that the company had entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin). Yafo Capital acted as the exclusive financial advisor on this transaction.

Yafo Announces a JV with COFCO to Expand into Nutrition & Food

Feb,2018

In Feb. 2018, Yafo Capital announced a joint venture with the Nutrition & Health Research Institute (NHRI) of COFCO (China National Cereals, Oils and Foodstuffs Corporation), the world’s third largest agriculture company, to expand into nutrition and health market and agro sector. The JV will be the first IP/tech-transfer company under Central State-Owned Enterprises (CSOEs).

Yafo Capital Reaches a Strategic Partnership with Xixian Capital in Fund Management

November 30, 2017

On November 30, 2017,Yafo Capital reached a strategic partnership with Xixian Financial Holdings, a wholly owned subsidiary of Xixian New Area, China's seventh State-level development district , to invest and bring global technologies to China. Yafo Capital and Xixian Capital agreed to set up an investment fund of 5 billion RMB, with a first phase of 1 billion RMB, that will focus on healthcare, green-tech, food and agro tech, TMT, advanced manufacturing and other sectors. The fund will invest in foreign enterprises in the above sectors, aiming to bring global products and/or technologies to China in order to penetrate the Chinese market.

Benjamin Peng Shares Sino-Israel Investment Opportunities in The 5th One Belt, One Road Initiative Conference in Israel.

September 26th, 2017

Benjamin Peng, from Yafo Capital, shared his insights about China-Israel investment and business opportunities at the The 5th One Belt, One Road Initiative conference panel discussion on September 26th, 2017.

The Bnai Brith Moshe Dayan Golden Manorah Award to Benjamin Peng

Feb,2018

It is an NGO represented at the United Nations Organization, the European Council, UNESCO and the MERCOSUR. The numerous lodges of the B’nai B’rith (Sons of the Brith) have been created by some Free Masons. They have all over the USA, South America, Europe, Australia and Israel- wherever Jewish communities exist.

The Hillel of Silicon Valley Honors Qi Li

2016

In 2016, the Hillel of Silicon Valley honored Yafo’s own Qi Li for her Israel advocacy work in both the US and China. She is the first Chinese and alumni student to be honored by the L’Dor V’Dor (“From Generation to Generation”) program in Hillel of Silicon Valley.

Love without Boundaries – Jewish Refugees in Shanghai

Feb,2018

A Yafo Capital sponsored art exhibition called “Love without Boundaries – Jewish Refugees in Shanghai” opened at the International Convention Center in Jerusalem on May 10th. The exhibition enshrined the history of Jews seeking shelter in Shanghai during WWII.

ACCESS CHINA Biotech Forum @ Bio Convention Week 2021

June 9th-18th, 2021

The largest China oriented healthcare partnering event – We are honored to invite you to our “ACCESS CHINA Biotech Forum @ Bio Convention Week 2021”,which will take place on June 9th-18th, 2021. This conference is the largest China oriented corporate access event with 100+ company presentations, 10 keynote speeches, and 500+ participants during Bio Convention Week.

ACCESS CHINA Spring Forum 2021 | China Out-Licensing Event

March 18th-19th, 2021

Hundreds of biopharma executives congregated for ACCESS CHINA to meet with the potential partners for development, licensing or commercial collaborations. The two-day conference agenda included company presentations and panel discussion.

ACCESS CHINA FORUM 2021 @ JPM WEEK

Dec 21st 2020

(Shanghai, December 21, 2020) Shanghai YAFO Life Science and BioToChina.org are organizing ACCESS CHINA Forum 2021 to be held between January 4th and 22nd. As the largest China corporate access event during the JPM Conference weeks, ACCESS CHINA 2021 expects to host more than 30 keynote speakers and 100 company presentations from North America, Europe, China and Rest of Asia. We expect more than 1000 participants from China and the global biopharma industry and investment community. Over 90 global biopharma companies have confirmed presenting. 40+ presenters from China include Fosun, Tasly, Shanghai Pharma, Grand Pharma and 7 MNCs like Abbott, Bayer, MSD, BD, SERVIER, and etc.

2020 YAFO ACCESS CHINA Autumn Partnering Day

Oct 10th 2020

[October 10th, 2020 Qingdao] YAFO Life Science, along with our partners, has successfully organized ACCESS CHINA Autumn Event on September 25th at Shangri-La Hotel in Qingdao. We helped over 50 overseas companies to present about 140 assets in front of hundreds of big pharmaceutical companies in China.

2020 YAFO ACCESS CHINA Online Summer Partnering Day

Aug 21st 2020

YAFO Life Science, along with our partners, has successfully organized the largest online corporate access event between China and Western biopharma industry on July 31st. We helped 29 overseas companies from 8 countries covering America, Asia, Europe, and China efficiently present their assets online in front of hundreds of big pharmaceutical companies in China.

2020 YAFO ACCESS CHINA Online Spring Partnering Day

June 5th 2020

COVID-19 has a profound impact on global economy, and the healthcare industry has received high attention from the whole society. YAFO Life Science along with our partners has successfully organized the largest online corporate access event between China and Western biopharma industry on May 15th and 22nd. We helped 35 overseas companies from 10 countries covering America, Asia, Europe, and China efficiently present their assets online in front of hundreds of big pharmaceutical companies in China.

2020 YAFO ACCESS CHINA BD Forum

June 7th, 2020

YAFO Capital is organizing 2020 ACCESS CHINA BD Forum at BIO International Convention 2020 on June 7, 2020 at the Omni Hotels & Resorts in San Diego. ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders to China, by directly meeting the right people for licensing and/or commercial partners. Our VIRTUAL ACCESS CHINA program offers forum participants opportunity to expand the exposure to much broader Chinese audiences.

YAFO Pre-JMP Ski Lake Tahoe and YAFO JPM Mixing Dinner 2020

Jan 10th, 2020 | Lake Tahoe; Jan 15th, 2020 | San Francisco

Following the YAFO JPM Mixing Dinner 2019, YAFO Capital together with Renexes and CHBD will provide an exciting Pre-JPM networking event that combining ski and fireside chat this year. The Mixing Dinner in San Francisco will include 50 to 100 people this year from China, Japan and US. The Pre-JPM Ski Tahoe and the Bio Fireside Chat event will be held at a ski resort in Lake Tahoe.

China Healthcare Investment Conference (CHIC)

March 26 -28, 2019 | Shanghai, China

In 2010, recognizing that the healthcare reform and industry growth was spurring a new wave of emerging Chinese healthcare companies, a group of investors led the efforts to organize China Healthcare Investment Conference (CHIC). This prestigious event has since grown into the most powerful platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the industry.

2019 Forum on Discovery & Development of NASH Drugs

March 29-30, 2019 | Shanghai

NASH (non-alcoholic steatohepatitis) is a huge unmet clinical need, and behind it is a new drug opportunity that cannot be missed.

一周医刊|CAR-T,基因测序受资本追捧热度不减!

2018-03-12

CAR-T再受追捧,药明康德与JUNO联姻公司药明巨诺获9000万美元A轮融资。

一周医刊|含金汤匙出生 Viela剥离出阿斯利康同时获2.5亿美金

2018-03-06

含金汤匙出生:Viela Bio剥离出阿斯利康同时获2.5亿美金融资;站在巨人的肩膀上:由illunima创立的血液诊断独角兽公司Grail拟在港上市。

二月医刊 | 罗氏、哈药、乐普又搞大动作!

2018-02-26

狗年第一篇医刊!祝大家狗年旺旺旺!让我们一起来看各医疗巨头又搞了哪些大动作~

一周医刊 | 亚马逊联手巴菲特与摩根大通建立医疗公司

2018-02-05

亚马逊联手巴菲特与摩根大通建立医疗公司 为自家员工谋福利;国内心理健康管理公司安肯医疗获国药资本数千万人民币融资;叮当快药和WeGene完成新一轮融资,互联网医疗迎来新零售风口。

一周医刊 | 赛诺菲开启买买买模式

2018-01-29

赛诺菲开启买买买模式,一周两连发,连续加码血液疾病业务;中国公司晶泰科技致力于利用AI技术进行药物研发,获得科技巨头谷歌、腾讯等的青睐。